Yongli Yang

Exploring heterogeneity in survival benefit of neoadjuvant therapy for triple-negative breast cancer using causal survival forests.

INTRODUCTION The individual survival benefit of neoadjuvant therapy (NAT) for patients with triple-negative breast cancer (TNBC) remains uncertain. This study aimed to evaluate the individualized treatment effect (ITE) of NAT on event-free survival (EFS) in patients with TNBC using causal survival forests. METHODS Th...

Safety and immunogenicity of inactivated human Rotavirus vaccine in young children and infants: a randomized, placebo-controlled, double-blind, phase I clinical trial

IRV was well tolerated, with no vaccine-related SAEs in any of the cohorts; the authors observed clinically manageable transient mild-to-moderate fever in the high dose infant group and the 3-dose schedule outperformed the 2-dose regimen.

A longitudinal study of socioeconomic status and cognitive function in middle-aged and older adults in China: random intercept cross-lagged panel analysis.